Lupin ties up with Amman Pharma for commercialisation of biosimilar product
- Country:
- India
Drug firm Lupin on Friday said it has tied up with Amman Pharma to market a biosimilar product in the Middle East region.
The company has inked a licensing pact for the commercialisation and marketing of Ranibizumab, a biosimilar of Lucentis, in various countries including Saudi Arabia, UAE, Iraq and Lebanon.
Ranibizumab is indicated for the treatment of patients with neovascular age-related macular degeneration, macular edema following retinal vein occlusion (RVO) and diabetic macular edema, among others.
Shares of the company on Friday ended 2.04 per cent down at Rs 1,180.20 apiece on the BSE.
ALSO READ
-
Lebanon’s Children Cannot Lose More of Their Childhood, UNICEF Chief Urges Action
-
Lebanon’s Children Face Hunger, Lost Schooling and Work as Families Reach the Brink
-
Lebanon’s Small Business Owners Build Skills and Market Links With EU and ILO Support
-
Lebanon and ILO Move to Modernize Cooperatives and Strengthen Rural Livelihoods
-
UNDP Urges Recovery From Day One as 160 Million People Risk Being Trapped in Crisis
Google News